IDIX Share Price

Open 24.48 Change Price %
High 24.50 1 Day 0.05 0.20
Low 24.46 1 Week 0.00 0.00
Close 24.50 1 Month 0.00 0.00
Volume 5094372 1 Year 0.00 0.00
52 Week High 81.40
52 Week Low 0.00
IDIX Important Levels
Resistance 2 24.54
Resistance 1 24.52
Pivot 24.49
Support 1 24.48
Support 2 24.46
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX)

IDIX Technical Analysis 5
As on 5th Aug 2014 IDIX Share Price closed @ 24.50 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 8.97 & Strong Buy for SHORT-TERM with Stoploss of 19.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
IDIX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
IDIX Other Details
Segment EQ
Market Capital 494027168.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.idenix.com
IDIX Address
IDIX
320 Bent Street
4th Floor
Cambridge, MA 02141
United States
Phone: 617-995-9800
Fax: 617-995-9801
IDIX Latest News
Interactive Technical Analysis Chart Idenix Pharmaceuticals, Inc. ( IDIX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Idenix Pharmaceuticals, Inc.
IDIX Business Profile
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.